HEMARINA, a French Biotechnology company developing breakthrough innovation for therapeutical applications using marine oxygen carrier, today announced that it has recently entered into a Cooperative Research and Development Agreement (CRADA) with the US Naval Medical Research Center for the use of HEMOxycarrier, the last generation of universal oxygen carrier. The CRADA, titled, Advancing Oxygen Therapeutic Agent development by evaluating the vasoactivity, oxygen carrying capacity, and effectiveness of HEMARINA-M101 (HEMOXYcarrier) in a non-clinical model as a pre-hospital resuscitation fluid for traumatic brain injury, with or without hemorrhagic shock is a three-year study that will test the HEMOXYcarrier on laboratory models.
This research responds to the identified medical need to improve pre-hospital aid of traumatic brain injury (TBI), which may be complicated by hemorrhagic shock (HS), by evaluation novel oxygen therapeutics that may reduce neurological damage in the immediate post-injury phase. This novel generation of oxygen therapeutic agent should be screened for potential use. Therefore, a screening survey is proposed to evaluate HEMOXYcarrier for pre-hospital use in combat casualties with TBI/HS. The financial conditions were not being disclosed.
"The overall objective of this research agreement is the evaluation of the HEMOXYcarrier product in the pre-hospital setting for casualties with polytrauma TBI/HS" said Dr Franck ZAL, HEMARINA’s Chief Executive Office and Chief Scientific Officer. Dr Franck ZAL also indicated that the preclinical studies already obtained by the company and by a research group of the University of California, San Diego on this product are very positive and do not possess the adverse effects demonstrated for the other generations of the Hemoglobin Oxygen Carrier (HBOC). Indeed, other HBOC were manufactured using chemically modified intracellular vertebrate hemoglobin (bovine and human) in order to work extracellularly, whereas HEMOXYcarrier is no viscous and composed of giant extracellular hemoglobins, which was already selected by the evolution millions of years ago and work already free in the circulation of marine organisms, and do not provoke vasoconstriction after perfusion on animal models.